Marco Quarta

Company: Rubedo Life Sciences

Job title: Chief Scientific Officer

Seminars:

A Novel First-in-Class Senolytic Therapy for Treating Various Chronic Inflammatory Skin Conditions 4:00 pm

Chronic skin conditions like atopic dermatitis, psoriasis, and rosacea share an inflammatory environment that hinders healing Senescent cells contribute to this inflammation, driving immune responses that worsen disease progression and tissue degeneration, especially with aging Rubedo's Alembic platform identifies different types of senescent cells in diseased tissues. Using this platform, Rubedo develops selective senolytic drugs…Read more

day: Conference Day Two